National and international developments in cancer, health and policy. Produced in collaboration with the Press Association unless otherwise stated.
NICE has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England.
A targeted cancer drug has been approved for use on the NHS in Scotland for patients with newly diagnosed ovarian cancer that’s responded to chemotherapy.
A treatment option for some people with bladder cancer, currently available through the CDF has been given an initial ‘no’ for routine use in England.
Two new cancer treatment options have been accepted for use in Scotland for some patients living with breast and kidney cancer.
A new treatment for early stage breast cancer will be made available for certain patients on the NHS in England.